TheNewswire / Hamilton, ON, November 14, 2017
CTT Pharmaceuticals Holdings, Inc., an innovative life sciences company which provides disruptive proprietary drug delivery technologies designed to improve patient outcomes and experiences, today would like to provide a corporate update.
2017 YTD Achievements and Anticipated Goals
– CanniMed Therapeutics, our exclusive Canadian licensee in the Medical Cannabis industry has submitted it’s application to Health Canada in regards to our proprietary sub-lingual wafer.
– US Patent and Trademark Office has issued US Patent # 14921501. This brings our patent portfolio to 4 issued patents, 2 pending and a PCT.
– Annual Report for 2016 has just been submitted to the OTC Markets and the 3 quarters of 2017 are currently being prepared and will be filed shortly.
– Currently in discussions with potential joint-venture partners and Pharmaceutical companies to license and commercialize various applications of it’s Oral Thin Film Wafer.
“We expect to be formalizing our agreements with our potential joint-venture partners shortly” said Dr Pankaj Modi, CEO of CTT Pharmaceuticals, ” In addition we are moving forward with our exclusive Canadian licensee CanniMed Therapeutics in obtaining Health Canada’s approval for our Oral Thin Film Wafer”
About CTT Pharmaceuticals Holdings, Inc.
CTT’s principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the “Wafer”). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases including pain management.
The Oral Thin Film (Wafer) formulation is protected by several Canadian and US Patents. CTT’s oral fast dissolving drug delivery systems will consist of edible thin films (wafers) that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.
Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its Wafer technology will be one of the first to gain use in major markets such as pain management.
For more information, please visit our website: www.cttpharmaceuticals.com
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.
Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including our future sales, income and financial position. The forward-looking statements included in this news release are made as of the date of this news release and CTT Pharmaceutical Holdings not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities law.
For more information or to schedule an interview, please contact:
Dr. Pankaj Modi
866 803 8386